Stress & Adrenal
What Causes Anxiety in Menopause?
Anxiety is one of the most disruptive — and least discussed — symptoms of menopause, affecting up to 51% of women during the perimenopausal transition. It isn't simply stress or personality; it's a physiological cascade driven by hormonal, adrenal, and neurochemical shifts that are measurable and, in many cases, addressable with the right data.
What Causes Anxiety in Menopause?
Yes, menopause genuinely causes anxiety — it isn't just stress or a mental health label. Declining estrogen disrupts GABA and serotonin signaling, destabilizes the HPA axis, and can unmask underlying thyroid dysfunction, producing real neurochemical anxiety. The main caveat: the severity varies enormously based on baseline cortisol reserve, thyroid status, and magnesium levels, so a one-size approach rarely works.
Anxiety affects an estimated 40–51% of women during perimenopause and early menopause — a rate significantly higher than in premenopausal years (Bromberger & Kravitz, Archives of General Psychiatry 2011; PMID: 21383262). Understanding why requires looking at the biological root causes, not just the symptom on the surface.
---
Menopause Root Causes: Why Hormonal Decline Triggers the Nervous System
The dominant trigger is the loss of estrogen's moderating role in the central nervous system. Estrogen up-regulates GABA-A receptor sensitivity — GABA is the brain's primary inhibitory neurotransmitter, the chemical that quiets neural noise and produces calm. As estradiol falls during perimenopause, GABA signaling weakens, leaving the nervous system in a more excitable, reactive state.
At the same time, estrogen supports serotonin synthesis and slows serotonin reuptake. When estrogen drops, serotonin availability decreases, and the threshold for anxious arousal falls (Lokuge et al., Journal of Clinical Psychiatry 2011; PMID: 21903023). This is one reason that women who had no prior history of anxiety can develop it seemingly out of nowhere in their mid-40s.
Progesterone matters too. Progesterone's metabolite, allopregnanolone, is a potent positive allosteric modulator of GABA-A receptors — essentially a natural anxiolytic. Progesterone typically declines before estrogen in perimenopause, so GABA support is eroded even earlier than most clinicians expect. This phase mismatch between progesterone and estrogen is one of the least-appreciated drivers of perimenopausal anxiety.
Finally, estrogen withdrawal sensitizes the amygdala — the brain's threat-detection center — making it more reactive to neutral or mildly stressful stimuli. The practical experience: normal life stressors that were previously manageable now feel overwhelming or even catastrophic.
If you're also experiencing low mood in menopause, it's worth knowing that the same estrogen-serotonin pathway drives both symptoms, which is why they frequently co-occur and may respond to overlapping interventions.
---
Anxiety Root Causes Beyond Estrogen: The HPA Axis and Cortisol
Estrogen doesn't operate in isolation. The hypothalamic-pituitary-adrenal (HPA) axis — the cortisol-generating stress system — is co-regulated by estrogen. As estrogen falls, HPA reactivity increases: the axis fires more readily, produces more cortisol per stressor, and takes longer to return to baseline. This phenomenon is sometimes called HPA hyperreactivity, and it's measurable in saliva or serum cortisol.
Chronic HPA hyperreactivity produces a vicious cycle. Elevated cortisol suppresses progesterone synthesis (the "pregnenolone steal"), further depleting the very neurosteroids that calm GABA-A receptors. It also disrupts sleep — a direct cause of the night sweats and sleep disruption that make menopausal anxiety worse at night — and impairs insulin sensitivity, which compounds mood instability through blood glucose swings.
A 2015 randomized controlled trial of ashwagandha (KSM-66 at 300 mg twice daily) in chronically stressed adults found a 27.9% reduction in serum cortisol over 60 days versus placebo (Chandrasekhar et al., Indian Journal of Psychological Medicine 2012; PMID: 23439798). While this trial was not menopause-specific, HPA hyperreactivity is the shared mechanism, making adrenal-targeted interventions relevant to this population.
Additionally, magnesium plays an underappreciated role in HPA regulation. Magnesium acts as a natural brake on NMDA glutamate receptors — the excitatory counterpart to GABA — and deficiency is associated with increased cortisol output and subjective anxiety (Boyle et al., Nutrients 2017; PMID: 28445426). Dietary magnesium intake falls far short of the 310–320 mg RDA for most adult women, and absorption declines further with age.
For those experiencing heart palpitations alongside anxiety, this HPA-cortisol pathway is frequently the shared root cause — adrenaline spikes that follow cortisol surges can trigger both symptoms simultaneously.
---
What Causes Hypothyroidism to Worsen Menopausal Anxiety?
Thyroid dysfunction is one of the most commonly overlooked amplifiers of menopausal anxiety, and the overlap is not coincidental. Estrogen modulates thyroid-binding globulin (TBG) levels, and as estrogen fluctuates in perimenopause, TBG shifts can alter how much free T3 and T4 are bioavailable — even when TSH looks normal on a standard panel.
Both hypothyroidism and subclinical hypothyroidism (TSH 2.5–10 mIU/L with symptoms) are associated with increased anxiety, depression, and cognitive fog. Conversely, if TSH dips into hyperthyroid territory — which can also occur transiently in perimenopause due to fluctuating TBG — anxiety, palpitations, and insomnia become prominent.
The critical clinical point: a TSH alone is insufficient. Free T3 and free T4 provide a more complete picture of thyroid function, and thyroid peroxidase (TPO) antibodies screen for Hashimoto's thyroiditis, which increases in prevalence in perimenopausal and postmenopausal women. An abnormal result here explains why anxiety persists despite adequate hormonal support.
Nutrient cofactors also matter. Selenium, as selenomethionine, is required for the conversion of T4 to active T3 via the deiodinase enzymes. A 2002 RCT found that 200 mcg of selenomethionine significantly reduced TPO antibody titers in Hashimoto's patients over 3 months (Gärtner et al., Journal of Clinical Endocrinology & Metabolism 2002; PMID: 11932302). Iodine, zinc, and iron are additional cofactors; a deficiency in any one of them can impair thyroid output and amplify the anxiety burden.
---
The Biomarkers Worth Checking
If you're experiencing menopause-related anxiety, the following labs give a functional picture of what's driving it:
| Biomarker | Standard Range | Functional Optimal | Why It Matters |
|---|---|---|---|
| Estradiol (E2) | Varies by phase | >50 pg/mL premenopause | Anchors GABA/serotonin tone |
| Progesterone | Varies by phase | >2 ng/mL mid-luteal | Allopregnanolone precursor |
| Free T3 | 2.0–4.4 pg/mL | 3.2–4.0 pg/mL | Active thyroid hormone |
| Free T4 | 0.8–1.8 ng/dL | 1.1–1.5 ng/dL | Conversion capacity |
| TSH | 0.5–4.5 mIU/L | 1.0–2.0 mIU/L | Pituitary thyroid signal |
| TPO Antibodies | <35 IU/mL | <35 IU/mL | Screens for Hashimoto's |
| Serum Cortisol (AM) | 6–23 mcg/dL | 12–18 mcg/dL | HPA output |
| Red Blood Cell Magnesium | 4.2–6.8 mg/dL | 5.5–6.5 mg/dL | More sensitive than serum Mg |
| Fasting Glucose | <100 mg/dL | 70–90 mg/dL | Blood sugar impacts mood stability |
Note: these functional optimal ranges are used in integrative and functional medicine practice and may differ from your lab's reference range. Always interpret results with a qualified clinician. High fasting glucose is an increasingly recognized co-driver of anxiety and mood instability in perimenopausal women — insulin resistance and cortisol dysregulation are closely linked.
---
The Protocol: A Structured Approach to Menopause-Related Anxiety
- Get a complete hormone and thyroid panel — not just TSH and estradiol. Include free T3, free T4, TPO antibodies, progesterone, and DHEA-S.
- Assess magnesium status via red blood cell (RBC) magnesium — serum magnesium is frequently normal even when intracellular stores are low.
- Address sleep disruption early — HPA hyperreactivity is substantially worsened by poor sleep. Treat night sweats and insomnia as primary targets, not secondary complaints.
- Support adrenal resilience through adaptogenic herbs where cortisol is elevated; choose evidence-based options with human trial data.
- Optimize thyroid micronutrient cofactors if thyroid function is suboptimal — selenium, zinc, and iron all feed the T4-to-T3 conversion pathway.
- Use dietary strategies to stabilize blood glucose — erratic glucose amplifies cortisol spikes and directly worsens anxiety.
- Consider mind-body techniques as evidence-based adjuncts — an 8-week mindfulness-based stress reduction (MBSR) program reduced anxiety scores in perimenopausal women in a 2019 trial (Sood et al., Menopause 2019; PMID: 30562276).
- Consult a healthcare provider before beginning any supplementation, especially if thyroid or hormonal medications are involved.
Muscle loss and metabolic slowdown — both driven by the same hormonal decline — can compound anxiety by worsening body image and energy levels. Understanding what causes muscle loss in menopause may help you address both symptoms within the same intervention framework.
---
What This Means for Your Formula
Personalized supplementation for menopausal anxiety looks very different depending on which root cause is primary. That's why Ones uses blood work, wearable data, and health history to build a formula calibrated to your actual findings — not a generic women's blend.
For elevated cortisol and HPA hyperreactivity, Ones includes KSM-66 Ashwagandha at 600 mg — the clinically studied dose used in the Chandrasekhar 2012 trial. For most mass-market adaptogens, standardization and dosing fall short of what studies actually used; the difference matters.
For thyroid micronutrient support, Ones carries selenomethionine at 200 mcg — the same form and dose used in the Gärtner 2002 trial showing reduced TPO antibody titers in Hashimoto's patients. This is included only when thyroid findings in the user's data support it, not by default.
For magnesium insufficiency — one of the most common findings in perimenopausal women — Ones uses Magnesium Glycinate as part of its Magnesium Complex blend, a highly bioavailable chelated form that supports both HPA regulation and GABA receptor function without the laxative effect of magnesium oxide. The Ones AI also factors in your capsule budget, building a 6 or 9-capsule daily plan based on your actual findings rather than giving everyone the same formula.
This targeted, data-driven approach means your formula addresses the anxiety mechanism that applies to you — whether that's adrenal, thyroid, or neurotransmitter-driven — rather than guessing.
---
Key Takeaways
- Menopausal anxiety is physiological, driven primarily by falling estrogen's effect on GABA and serotonin signaling, not simply emotional stress.
- The HPA axis becomes hyperreactive as estrogen declines, producing excess cortisol that further depletes calming neurosteroids like allopregnanolone.
- Thyroid dysfunction amplifies anxiety in menopause — subclinical hypothyroidism and Hashimoto's both increase in prevalence during this transition and are frequently missed on standard TSH-only panels.
- Magnesium deficiency is common in perimenopausal women and worsens both HPA overactivity and GABA receptor function; RBC magnesium is a more reliable test than serum magnesium.
- Key biomarkers include free T3, free T4, TPO antibodies, AM cortisol, RBC magnesium, and fasting glucose — not just estradiol and TSH.
- Personalized supplementation targeting your specific root cause — adrenal, thyroid, or neurotransmitter-based — is more effective than a generic approach, which is where data-driven platforms like Ones offer a meaningful advantage.